Drug intelligence / Profile preview

astegolimab

Development stage: Phase 3
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

Astegolimab is a monoclonal antibody developed for the treatment of severe asthma and is under investigation for chronic obstructive pulmonary disease (COPD). It acts by targeting the ST2 receptor (also known as IL1RL1), thereby interfering with downstream signaling pathways involved in inflammation. Astegolimab is administered via subcutaneous injection, typically every two or four weeks, and has been studied in both asthma and COPD populations, including those with frequent exacerbations. The drug remains investigational and has not yet received regulatory approval[1][2][3][4][5][6][7].

Other names: ST2 mabST-2 mabST 2 mab

Targets

IL1RL1 (Interleukin 1 receptor-like 1 protein)

Beyond the preview

Go deeper on astegolimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on astegolimab.

Explore the full profile